Thalidomide-O-amido-C6-NH2 TFA
CAS No. 1950635-14-9
Thalidomide-O-amido-C6-NH2 TFA ( Cereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA; E3 Ligase Ligand-Linker Conjugates 25 Trifluoroacetate; Thalidomide-O-amido-C6-NH2 TFA )
Catalog No. M26948 CAS No. 1950635-14-9
Thalidomide-O-amido-C6-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 42 | Get Quote |
|
5MG | 69 | Get Quote |
|
10MG | 102 | Get Quote |
|
25MG | 170 | Get Quote |
|
50MG | 250 | Get Quote |
|
100MG | 392 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameThalidomide-O-amido-C6-NH2 TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionThalidomide-O-amido-C6-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.
-
DescriptionThalidomide-O-amido-C6-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
SynonymsCereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA; E3 Ligase Ligand-Linker Conjugates 25 Trifluoroacetate; Thalidomide-O-amido-C6-NH2 TFA
-
PathwayOthers
-
TargetOther Targets
-
RecptorDNA replication; HCMV; Nucleoside Analogue
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1950635-14-9
-
Formula Weight544.5
-
Molecular FormulaC23H27F3N4O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(=O)C(F)(F)F.NCCCCCCNC(=O)COc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hamada A, et al. Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet. 2002;41(10):705-18.
molnova catalog
related products
-
NSC622608
NSC622608 is a small-molecule ligand for V-domain Ig suppressor of T-cell activation (VISTA) which is an immune checkpoint that affects the ability of T-cells to attack tumors.
-
Luteolin 7-rutinosid...
Luteolin-7-rutinoside has both antifungal activities and anti-arthritic, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
-
Fibrinopeptide B, hu...
Fibrinopeptide B (FPB) is produced during the cleavage of fibrinogen, by thrombin, to fibrin monomer.